A Phase 2 interventional study of Varenicline in Smoking, sponsored by Pfizer. Completed at 8 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-10.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing varenicline in Smoking — none open to participants now, none under way, none of them phase 3. Varenicline · Smoking.
Among the 57 studies testing varenicline in Smoking, this one is the 38th largest by enrollment, is the only one that started in 2004, is one of 10 in phase 2, and was the 8th registered.
1,513 studies on the registry are indexed under Smoking; 194 are open to participants now.
Browse Smoking studies →None of the 57 studies testing varenicline in Smoking is open now. The open studies under Smoking, anywhere →
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 140 Smoking studies recruiting now, 74 (53%) set no upper age limit and 48 (34%) stop at 75 or younger; 3 take children under 18; 65 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 12 · Phase 4 20
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 115 across 1,165 interventional studies indexed under Smoking.
Median enrollment 83 across the 57 interventional studies. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 57 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Smoking — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 57 studies testing varenicline in Smoking, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of varenicline in Japanese smokers. Efficacy is evaluated by continuous quit rate and withdrawal symptoms of smokers. Safety is evaluated by adverse events, laboratory tests, and other safety tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Varenicline
0.5 mg BID for 7 weeks
Also known as: Chantix, Champix, CP-526,555
Carbon monoxide (CO)-confirmed 4-week continuous quit rate (4-week CQR) from Weeks 4 to 7.
Time frame: Weeks 4-7
CO-confirmed 7-day Point Prevalence from Week 2 through Week 7.
Time frame: Weeks 2-7
Continuous abstinence rate from target quit date (TQD) from Week 2 through Week 7.
Time frame: Weeks 2-7
Average number of daily cigarettes smoked from Week 2 through Week 7.
Time frame: Weeks 2-7
Assessment of withdrawal symptoms by Minnesota Nicotine Withdrawal Scales (MNWS) from Week 2 through Week 7.
Time frame: Weeks 2-7
Assessment of satisfaction (desirable and aversive effects) obtained from smoking by Smoking Effects Inventory (SEI) (administered only to subjects who had smoked since the previous assessment) from Week 2 through Week 7.
Time frame: Weeks 2-7
Assessment of tobacco craving by the Brief Questionnaire of Smoking Urges (QSU-Brief) from Week 2 through Week 7.
Time frame: Weeks 2-7
Assessment of the effect of smoking cessation on subjects' quality of life by the Smoking Cessation Quality of Life (SCQoL) questionnaire from Week 2 through Week 7.
Time frame: Weeks 2-7
Adverse events, laboratory test changes throughout the study.
Time frame: Weeks 1-7
The record gives a start of May 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline